Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 11:04 AM ET

Diversified Consumer Services

Company Overview of University of Minnesota

Company Overview

University of Minnesota is an educational institution that provides undergraduate and graduate programs. It offers courses in business administration, agriculture and life sciences, arts, medicine, engineering, mathematics, nursing and health sciences, and social services. University of Minnesota was founded in 1851 and is based in Minneapolis, Minnesota.

3 Morrill Hall

100 Church Street S.E.

Minneapolis, MN 55455

United States

Founded in 1851



Key Executives for University of Minnesota

President and Board of Regents
Age: 58
Vice President of Research
Age: 64
Vice President of Health Sciences and Dean of Medical School
Chief of Staff
Vice President for University Relations
Age: 59
Compensation as of Fiscal Year 2015.

University of Minnesota Key Developments

University of Minnesota Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-09-2015 03:00 PM

University of Minnesota Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-09-2015 03:00 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Joseph Metzger, Professor & Chair, Department of Integrative Biology & Physiology.

Calyxt Signs Licensing Agreement with University of Minnesota

Calyxt Inc. has signed an exclusive licensing agreement with The University of Minnesota to grant Cellectis the worldwide rights to use the technology covered by the patent rights of the family PCT/US2013/046495 entitled Gene Targeting Using Replicating DNA Molecules. Both the partners are based in the US.

Fate Therapeutics Enters into Research Collaboration with University of Minnesota on Development of Natural Killer Cell-Based Immuno-Oncology Candidates

Fate Therapeutics entered into a research collaboration with the University of Minnesota focused on the development of natural killer (NK) cell-based immuno-oncology candidates. Fate Therapeutics will leverage the University's pioneering work on NK cell-based therapies, as well as its own cell-programming and stem-cell technology platform to develop 'off-the-shelf' candidates with anti-tumour activity. The collaboration will focus on two main therapeutic projects, one related to optimisation of 'adaptive' NK cells, and the other focused on utilisation of induced pluripotent stem cells (iPSCs) to derive NK cell-based candidates. Based on the terms of the agreement, Fate Therapeutics has the option to obtain exclusive patent rights to candidates resulting from the collaboration.

Similar Private Companies By Industry

Company Name Region
Auto Hound, Inc. United States
Northwest Evaluation Association United States
Dale & Gensburg, P.C. United States
Car Wash Enterprises, Inc. United States
Children's Documentary Network LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact University of Minnesota, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at